Second Launch Of Jago Geomatrix System
Mundipharma GmbH of Germany has launched Cordicant-Uno, a once-daily formulation of nifedipine for hypertension and angina. This is the second launch of a product using Jago Pharma's proprietary Geomat-rix controlled-release drug delivery system. The first product to use the technol-ogy was Dilacor XR, a once-daily formulation of diltiazem marketed in the USA by Rhone-Poulenc Rorer.
Jago says that another Geomatrix-formulated drug is due for launch in Europe in the near future and is undergoing the final stages of regulatory review, but declined to identify the product. The company recently completed pilot studies in collaboration with Gensia for the development of a Geomatrix formulation of nifedipine in the USA (Marketletter July 18).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze